|
Orthologous residues
|
|
NuaK1 (human): S600‑p, NuaK1 (mouse): S601‑p, NuaK1 (rat): S600‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody, western blotting
|
|
Disease tissue studied:
colorectal cancer, colorectal carcinoma, pancreatic cancer, pancreatic carcinoma
|
|
Relevant cell lines - cell types - tissues:
DLD1 (intestinal), PANC-1 (pancreatic), SW480 (intestinal)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
Akt1 (human)
|
pharmacological activator of upstream enzyme, phospho-antibody, transfection of dominant-negative enzyme, pharmacological inhibitor of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
IGF-1
|
|
|
|
increase
|
|
|
LY294002
|
IGF-1
|
|
|
inhibit treatment-induced increase
|
|
|
U0126
|
IGF-1
|
|
|
no effect upon treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
activation
|
|
Effect of modification (process):
cell motility, altered
|